MarketCap
Facebook
X
TelegramAnnual report 2025
added 12-05-2025
The Cooper Companies Income Statement 2011-2026 | COO
Annual Income Statement The Cooper Companies
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Market Cap |
16.3 B | 65.9 B | 65.6 B | 61.5 B | 20.6 B | 17.8 B | 15.4 B | 13.7 B | 11.8 B | 8.02 B | 7.06 B | 8.13 B | 6.32 B | 4.6 B | 2.96 B |
Shares |
199 M | 199 M | 198 M | 197 M | 49.2 M | 49.1 M | 49.1 M | 49.2 M | 48.8 M | 48.8 M | 48.3 M | 48.1 M | 48 M | 48.4 M | 48.3 M |
Historical Prices |
82 | 331 | 331 | 312 | 419 | 363 | 321 | 254 | 218 | 175 | 134 | 162 | 124 | 92.2 | 70.3 |
Net Income |
375 M | 392 M | 294 M | 386 M | 2.94 B | 238 M | 467 M | 140 M | 373 M | 274 M | 204 M | 270 M | 296 M | 248 M | 175 M |
Revenue |
4.09 B | 3.9 B | 3.59 B | 3.31 B | 2.92 B | 2.43 B | 2.65 B | 2.53 B | 2.14 B | 1.97 B | 1.8 B | 1.72 B | 1.59 B | 1.45 B | 1.33 B |
Cost of Revenue |
1.41 B | 1.3 B | 1.24 B | 1.17 B | 967 M | 896 M | 897 M | 900 M | 773 M | 794 M | 727 M | 626 M | 561 M | 521 M | 526 M |
Gross Profit |
2.68 B | 2.6 B | 2.36 B | 2.14 B | 1.96 B | 1.53 B | 1.76 B | 1.63 B | 1.37 B | 1.17 B | 1.07 B | 1.09 B | 1.03 B | 924 M | 805 M |
Operating Income |
683 M | 706 M | 533 M | 508 M | 506 M | 312 M | 547 M | 403 M | 429 M | 324 M | 237 M | 306 M | 306 M | 283 M | 228 M |
Interest Expense |
-16.4 M | -9.1 M | -14.9 M | 25 M | 23.1 M | 36.8 M | 68 M | 82.7 M | 33.4 M | 26.2 M | 18.1 M | 7.96 M | 9.17 M | 11.8 M | 17.3 M |
EBITDA |
1.06 B | 1.08 B | 901 M | 854 M | 815 M | 462 M | 674 M | 574 M | 498 M | 385 M | 288 M | 342 M | 371 M | 312 M | 248 M |
Operating Expenses |
- | - | - | - | - | - | 1.23 B | 1.2 B | 937 M | 849 M | 834 M | 785 M | 686 M | 636 M | 577 M |
General and Administrative Expenses |
1.63 B | 1.53 B | 1.5 B | 1.34 B | 1.21 B | 992 M | 996 M | 973 M | 799 M | 723 M | 713 M | 683 M | 597 M | 560 M | 513 M |
All numbers in USD currency
Quarterly Income Statement The Cooper Companies
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Shares |
199 M | 200 M | 200 M | 200 M | 199 M | 199 M | 198 M | 198 M | 198 M | 198 M | 198 M | 49.3 M | 49.3 M | 49.3 M | 49.1 M | 49.2 M | 49.3 M | 49.2 M | 49.1 M | 49.1 M | 49.1 M | 49.2 M | 49.3 M | 49.4 M | 49.5 M | 49.4 M | 48.9 M | 49 M | 49.1 M | 49.1 M | 48.8 M | 48.9 M | 48.9 M | 49 M | 48.3 M | 48.4 M | 48.6 M | 48.4 M | 48.2 M | 48.4 M | 48.6 M | 48.5 M | 48 M | 48 M | 48 M | 47.9 M | 48.5 M | 48.6 M | 48.8 M | 48.5 M | 47.7 M | 47.8 M | 48.1 M | 47.7 M | 46 M | 46.6 M | 47.3 M | 46.5 M |
Net Income |
98.3 M | 87.7 M | 104 M | - | 105 M | 88.9 M | 81.2 M | - | 85.3 M | 39.8 M | 84.6 M | 320 M | 98.4 M | 127 M | 95.3 M | 2.83 B | 616 M | 118 M | 90.5 M | 81.2 M | 55.2 M | 11.5 M | 103 M | 121 M | 120 M | 122 M | -122 M | 101 M | 101 M | 60.9 M | 75.8 M | 88.6 M | 104 M | 105 M | 51.4 M | 60.5 M | 87.9 M | 74.1 M | 61.2 M | 36.7 M | 45 M | 60.7 M | 71.8 M | 30.8 M | 88.1 M | 79.2 M | 74.7 M | 57.4 M | 89 M | 75.1 M | 54.6 M | 71.9 M | 66.9 M | 54.9 M | 39.2 M | 56.6 M | 44.2 M | 35.4 M |
Revenue |
1.06 B | 1 B | 965 M | - | 1 B | 943 M | 932 M | - | 930 M | 877 M | 858 M | 49.3 M | 843 M | 830 M | 787 M | 2.16 B | 763 M | 720 M | 646 M | 682 M | 578 M | 525 M | 628 M | 692 M | 679 M | 654 M | 590 M | 652 M | 660 M | 631 M | 499 M | 562 M | 556 M | 522 M | 450 M | 519 M | 515 M | 484 M | 445 M | 456 M | 462 M | 435 M | 405 M | 468 M | 432 M | 412 M | 380 M | 412 M | 412 M | 384 M | 326 M | 396 M | 378 M | 345 M | 293 M | 361 M | 351 M | 325 M |
Cost of Revenue |
368 M | 323 M | 304 M | - | 340 M | 311 M | 308 M | - | 320 M | 294 M | 300 M | 857 M | 291 M | 297 M | 230 M | 710 M | 247 M | 232 M | 220 M | 638 M | 217 M | 201 M | 210 M | 660 M | 229 M | 222 M | 219 M | 679 M | 233 M | 227 M | 187 M | 565 M | 200 M | 178 M | 188 M | 571 M | 198 M | 185 M | 169 M | 525 M | 189 M | 167 M | 142 M | 438 M | 152 M | 144 M | 139 M | 413 M | 144 M | 130 M | 116 M | 378 M | 138 M | 124 M | 117 M | 389 M | 149 M | 124 M |
Gross Profit |
692 M | 679 M | 660 M | - | 663 M | 631 M | 624 M | - | 610 M | 583 M | 558 M | 1.6 B | 552 M | 532 M | 451 M | 1.45 B | 516 M | 487 M | 426 M | 424 M | 361 M | 324 M | 418 M | 455 M | 451 M | 433 M | 371 M | 430 M | 427 M | 404 M | 312 M | 353 M | 356 M | 344 M | 262 M | 296 M | 317 M | 298 M | 276 M | 253 M | 273 M | 268 M | 263 M | 280 M | 281 M | 268 M | 240 M | 264 M | 268 M | 254 M | 210 M | 253 M | 240 M | 221 M | 177 M | 224 M | 203 M | 202 M |
Operating Income |
176 M | 185 M | 182 M | - | 192 M | 162 M | 153 M | - | 152 M | 96.3 M | 150 M | 404 M | 141 M | 133 M | 133 M | 377 M | 101 M | 143 M | 111 M | 212 M | 72 M | 28.6 M | 111 M | 400 M | 142 M | 147 M | 90.2 M | 280 M | 116 M | 74.7 M | 90.7 M | 321 M | 113 M | 117 M | 57.4 M | 250 M | 103 M | 89.8 M | 73.1 M | 194 M | 50.3 M | 71 M | 81.6 M | 267 M | 96.6 M | 88.9 M | 68.8 M | 244 M | 93.6 M | 81.5 M | 61.7 M | 204 M | 77.2 M | 65.4 M | 48.7 M | 161 M | 52 M | 60.3 M |
Interest Expense |
1.6 M | -16.1 M | -2.7 M | - | -300 K | -2.8 M | -3.2 M | - | -6 M | 26.1 M | 26.1 M | 34.5 M | 17.1 M | 10.8 M | 6.4 M | 18.1 M | 5.6 M | 6.1 M | 11.6 M | 30.1 M | 5.7 M | 12.8 M | 18.2 M | 53.3 M | 16.7 M | 18.5 M | 18.4 M | 59.9 M | 22.8 M | 18.7 M | 7.3 M | 23.3 M | 8.3 M | 7.7 M | 5.3 M | 20.9 M | 8 M | 7.6 M | 3.94 M | 13.3 M | 4.69 M | 4.69 M | 1.66 M | 4.71 M | 1.5 M | 1.56 M | 2.57 M | 7.27 M | 2.26 M | 2.44 M | 3.66 M | 9.05 M | 2.32 M | 3.07 M | 6.95 M | 14.4 M | 3.22 M | 4.27 M |
EBITDA |
226 M | 235 M | 273 M | - | 243 M | 212 M | 250 M | - | 198 M | 143 M | 239 M | 661 M | 181 M | 184 M | 209 M | 609 M | 139 M | 180 M | 182 M | 422 M | 211 M | 62.5 M | 180 M | 610 M | 282 M | 184 M | 157 M | 485 M | 251 M | 111 M | 138 M | 462 M | 207 M | 134 M | 111 M | 401 M | 204 M | 104 M | 116 M | 336 M | 138 M | 83.3 M | 113 M | 363 M | 160 M | 96.4 M | 100 M | 337 M | 156 M | 89 M | 87.5 M | 285 M | 130 M | 70.7 M | 71.6 M | 233 M | 98.4 M | 65 M |
General and Administrative Expenses |
422 M | 399 M | 388 M | - | 381 M | 380 M | 381 M | - | 375 M | 408 M | 331 M | 984 M | 343 M | 322 M | 261 M | 900 M | 352 M | 286 M | 258 M | 728 M | 233 M | 237 M | 250 M | 747 M | 250 M | 247 M | 226 M | 725 M | 251 M | 248 M | 189 M | 591 M | 209 M | 193 M | 174 M | 534 M | 182 M | 178 M | 174 M | 533 M | 192 M | 168 M | 158 M | 475 M | 161 M | 156 M | 151 M | 453 M | 152 M | 151 M | 132 M | 413 M | 144 M | 137 M | 113 M | 373 M | 134 M | 126 M |
All numbers in USD currency
The income statement is one of the three key financial reports of a company The Cooper Companies (alongside the balance sheet and the cash flow statement). It shows how the company makes money and what its expenses are:
- How much revenue the company earned
- How much it spent on production, personnel, marketing, taxes, etc.
- What profit remained in the end
Analyzing the income statement helps an investor understand whether the business generates stable and growing profits, how effectively the company controls its expenses, and whether it is capable of generating income in the future. Additionally, this analysis shows how the company copes with crises and economic cycles, and allows assessing the potential for stock price growth and dividend payments.
Features- The income statement may include both recurring and one-time items (for example, profit from the sale of assets). It is necessary to separate core metrics from one-off events for accurate analysis.
- Companies often publish interim reports (e.g., quarterly), which allows for more timely tracking of trends.
- A combined analysis of the income statement with the balance sheet and cash flow statement provides a comprehensive view of the company’s financial health.
Reports on the profits and losses of other stocks in the Medical instruments industry
| Issuer | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|
 |
Atrion Corporation
ATRI
|
- | - | $ 810 M |  USA |
 |
Becton, Dickinson and Company
BDX
|
$ 184.86 | 1.31 % | $ 53.2 B | USA |
 |
Baxter International
BAX
|
$ 21.74 | 1.85 % | $ 11.2 B | USA |
 |
Luminex Corporation
LMNX
|
- | - | $ 1.75 B | USA |
 |
Akers Biosciences, Inc.
AKER
|
- | -9.52 % | $ 20.6 M | USA |
 |
Antares Pharma, Inc.
ATRS
|
- | - | $ 955 M | USA |
 |
Cantel Medical Corp.
CMD
|
- | -1.18 % | $ 3.4 B | USA |
 |
CRH Medical Corporation
CRHM
|
- | - | $ 282 M | USA |
 |
Hill-Rom Holdings, Inc.
HRC
|
- | -0.05 % | $ 10.3 B | USA |
 |
Varian Medical Systems, Inc.
VAR
|
- | -0.02 % | $ 16.3 B | USA |
 |
Ekso Bionics Holdings
EKSO
|
$ 11.29 | -8.21 % | $ 228 M | USA |
 |
ICU Medical
ICUI
|
$ 155.85 | 4.08 % | $ 3.84 B | USA |
 |
Alcon
ALC
|
$ 82.21 | -1.21 % | $ 40.4 B |  Schweiz |
 |
AtriCure
ATRC
|
$ 32.79 | 1.27 % | $ 1.57 B | USA |
 |
electroCore
ECOR
|
$ 6.16 | -0.16 % | $ 34 K | USA |
 |
Harvard Bioscience
HBIO
|
$ 0.58 | -0.56 % | $ 24.6 M | USA |
 |
LeMaitre Vascular
LMAT
|
$ 92.55 | 0.75 % | $ 2.08 B | USA |
 |
AngioDynamics
ANGO
|
$ 11.22 | 0.13 % | $ 458 M | USA |
 |
InfuSystem Holdings
INFU
|
$ 7.9 | - | $ 163 M | USA |
 |
Haemonetics Corporation
HAE
|
$ 61.61 | 1.55 % | $ 3.1 B | USA |
 |
iRhythm Technologies
IRTC
|
$ 150.56 | -5.24 % | $ 4.82 B | USA |
 |
Isoray
ISR
|
- | 0.03 % | $ 108 M | USA |
 |
Glaukos Corporation
GKOS
|
$ 119.69 | 2.21 % | $ 5.8 B | USA |
 |
Repro Med Systems
KRMD
|
$ 4.72 | 0.64 % | $ 215 M | USA |
 |
OraSure Technologies
OSUR
|
$ 2.76 | -2.47 % | $ 205 M | USA |
 |
Masimo Corporation
MASI
|
$ 175.38 | 0.03 % | $ 9.35 B | USA |
 |
Intuitive Surgical
ISRG
|
$ 504.2 | 0.93 % | $ 180 B | USA |
 |
Merit Medical Systems
MMSI
|
$ 82.25 | 0.5 % | $ 4.79 B | USA |
 |
Microbot Medical
MBOT
|
$ 2.07 | -3.95 % | $ 21.1 M |  Israel |
 |
Nephros
NEPH
|
$ 4.14 | 6.43 % | $ 43 M | USA |
 |
NeuroMetrix
NURO
|
- | 5.05 % | $ 9.02 M | USA |
 |
Milestone Scientific
MLSS
|
$ 0.26 | -2.04 % | $ 20.7 M | USA |
 |
DENTSPLY SIRONA
XRAY
|
$ 12.63 | 0.88 % | $ 2.57 B | USA |
 |
Envista Holdings Corporation
NVST
|
$ 29.16 | 1.53 % | $ 4.9 B | USA |
 |
Pro-Dex
PDEX
|
$ 39.55 | 1.41 % | $ 130 M | USA |
 |
Pulse Biosciences
PLSE
|
$ 21.98 | -12.38 % | $ 1.48 B | USA |
 |
Predictive Oncology
POAI
|
- | - | $ 31.1 M | USA |
 |
Stereotaxis
STXS
|
$ 2.08 | -0.24 % | $ 168 M | USA |
 |
Repligen Corporation
RGEN
|
$ 136.76 | -0.34 % | $ 7.62 M | USA |
 |
ResMed
RMD
|
$ 258.04 | 0.68 % | $ 37.7 B | USA |
 |
BioLife Solutions
BLFS
|
$ 23.17 | -0.26 % | $ 1.07 B | USA |
 |
STERIS plc
STE
|
$ 250.32 | -0.34 % | $ 24.7 B | USA |
 |
Retractable Technologies
RVP
|
$ 0.67 | -3.48 % | $ 20.1 M | USA |
 |
STAAR Surgical Company
STAA
|
$ 17.65 | -1.29 % | $ 867 M | USA |
 |
Teleflex Incorporated
TFX
|
$ 115.88 | 3.65 % | $ 5.43 B | USA |
 |
Utah Medical Products
UTMD
|
$ 67.96 | 2.09 % | $ 247 M | USA |
 |
West Pharmaceutical Services
WST
|
$ 241.54 | -0.94 % | $ 17.5 B | USA |